Related Experiment Videos
Rationale and management of hyperlipidemia of the nephrotic syndrome
1Department of Clinical Nutrition, University of Texas Southwestern Medical Center, Dallas 75235-9052.
Insights
Hyperlipidemia, common in nephrotic syndrome, increases risks of atherosclerosis and kidney failure. Drug therapy, particularly cholesterol synthesis inhibitors, shows promise for managing these lipid abnormalities and preventing complications.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Hyperlipidemia, characterized by elevated cholesterol and triglycerides, is a common comorbidity in nephrotic syndrome.
- This lipid disorder poses potential risks for atherosclerosis and the progression of renal failure.
- Effective management of hyperlipidemia is crucial for mitigating these long-term vascular and renal complications.
Purpose of the Study:
- To review the therapeutic strategies for managing hyperlipidemia in patients with nephrotic syndrome.
- To evaluate the efficacy and safety of various lipid-lowering drugs in this specific patient population.
- To highlight the need for effective treatments to prevent vascular and renal complications associated with nephrotic hyperlipidemia.
Main Methods:
- Literature review of studies on hyperlipidemia treatment in nephrotic syndrome.
- Analysis of the effectiveness of bile acid-binding resins, nicotinic acid, HMG-CoA reductase inhibitors (e.g., lovastatin), fibric acids, and probucol.
- Assessment of potential side effects, including myopathy and renal complications.
Main Results:
- Dietary therapy alone is often insufficient for nephrotic hypercholesterolemia.
- Bile acid-binding resins and probucol show some cholesterol-lowering effects but may not be sufficient.
- HMG-CoA reductase inhibitors appear promising for both cholesterol and triglyceride reduction, but require further safety evaluation in nephrotic patients.
- Fibric acids primarily reduce triglycerides and have limited impact on cholesterol.
Conclusions:
- Drug therapy is essential for managing severe hyperlipidemia in nephrotic syndrome.
- HMG-CoA reductase inhibitors represent a promising therapeutic option, pending further safety data, especially regarding myopathy.
- Combination therapy, potentially including probucol, may be beneficial for achieving optimal lipid control.
Abstract:
Hyperlipidemia is usually present in patients with the nephrotic syndrome. The most common lipid abnormality is hypercholesterolemia, although as the disorder progresses, hypertriglyceridemia may develop. Elevated plasma lipids have two potential vascular consequences, namely, atherosclerosis and progression of renal failure. Neither of these complications has been proven with certainty, but there is growing evidence to indicate that both may be long-term consequences of the nephrotic syndrome. Therefore, effective therapy of hyperlipidemia, particularly elevated cholesterol levels, is needed as a protection against these complications. Since nephrotic hypercholesterolemia frequently is severe, dietary therapy, although a valuable adjunct, will not normalize cholesterol levels in most nephrotic patients. Thus, if effective serum cholesterol lowering is to be achieved, drug therapy will be required. Bile acid-binding resins have been shown to lower cholesterol levels in nephrotic patients, but the decline in cholesterol concentrations is usually insufficient to produce a marked reduction in coronary risk. Nicotinic acid theoretically should be useful for treatment of nephrotic hyperlipidemia, but it has not been adequately tested. The new drugs that inhibit cholesterol synthesis, e.g., lovastatin, appear to be highly promising for treating elevations of both serum cholesterol and triglycerides in the nephrotic syndrome. However, testing of these drugs in this condition has been limited, and the possibility of significant side effects in an appreciable portion of patients has not been ruled out. Of particular concern is the development of severe myopathy that can produce myoglobinuria and acute renal failure. This side effect is relatively rare in patients without the nephrotic syndrome, but its prevalence in the latter condition has not been determined. The fibric acids will lower triglyceride levels in nephrotic patients, but they are not effective in lowering cholesterol levels; consequently, they probably have little role in the treatment of nephrotic hypercholesterolemia. Finally, the drug probucol will lower cholesterol levels in nephrotic patients, although not to desirable levels; still, probucol could prove useful in combination with other cholesterol-lowering drugs.